Valuation: NetraMark Holdings Inc.

Market Cap 75.7M 53.96M 46.86M 43.56M 40.06M 5.15B 76.97M 514M 201M 2.57B 203M 198M 8.5B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 75.7M 53.96M 46.86M 43.56M 40.06M 5.15B 76.97M 514M 201M 2.57B 203M 198M 8.5B EV / Sales 2026 *
189x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-15 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
03-25 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
03-25 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
03-25 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
1 day+1.27%
1 week+2.56%
1 month+26.98%
3 months-13.98%
6 months-22.33%
Current year-27.27%
1 week 0.69
Extreme 0.69
0.85
1 month 0.6
Extreme 0.6
0.95
Current year 0.59
Extreme 0.59
1.28
1 year 0.59
Extreme 0.59
1.8
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
2.25
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap.
4/13/26 A Tax

Chairperson

434,178 0.4686%
2/19/26 A Option

Executive/Senior Manager

116,250 0.1354%
2/19/26 A Other

Executive/Senior Manager

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+1.27%+2.56%-41.61%+226.53% 53.96M
+3.02%+21.75%-12.89%+38.34% 3,451B
+0.65%+0.11%-22.29%+520.26% 295B
-0.22%+8.55%+91.43%+129.58% 95.39B
+2.16%+4.22%-6.73%+45.30% 93.64B
+4.41%+4.09%-38.63%-13.95% 74.44B
+0.47%+6.74%-31.86%+60.46% 65.38B
-1.82%+4.87%+9.06%+58.83% 45.4B
-26.85%-25.13%-74.16%-9.30% 25.43B
-0.79%+0.86%-30.60%-48.44% 30.53B
Average -1.77%+2.07%-15.83%+100.76% 417.61B
Weighted average by Cap. +2.48%+18.20%-12.05%+73.34%

Financials

2026 *2027 *
Net sales 401K 286K 248K 231K 212K 27.28M 408K 2.72M 1.07M 13.59M 1.07M 1.05M 45.01M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
31/07/26 CA$0.8000 +1.27% 30,645
30/07/26 CA$0.7900 +1.28% 2,190
29/07/26 CA$0.7800 -.--% 1,005
28/07/26 CA$0.7800 +9.86% 128,506
27/07/26 CA$0.7100 -8.97% 62,784

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock